Genelux Corporation(GNLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GNLX Genelux Corporation

Pre-Mkt 05-22 07:19:02 EDT

2.92

-0.01

-0.34%

High2.94	Low2.88	Vol51.51K
Open2.90	D1 Closing2.93	Amplitude1.99%
Mkt Cap130.58M	Tradable Cap106.49M	Total Shares44.72M
T/O150.22K	T/O Rate0.14%	Tradable Shares36.47M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GNLX","market":"US","secType":"STK","nameCN":"Genelux Corporation","latestPrice":2.92,"timestamp":1779393600000,"preClose":2.93,"halted":0,"volume":51505,"delay":0,"changeRate":-0.003412969283276529,"floatShares":36467700,"shares":44718438,"eps":-0.852035,"marketStatus":"Pre-Mkt","change":-0.01,"latestTime":"05-22 07:19:02 EDT","open":2.9,"high":2.94,"low":2.8816,"amount":150216.8304925,"amplitude":0.019932,"askPrice":3.69,"askSize":100,"bidPrice":2.62,"bidSize":27,"shortable":3,"etf":0,"ttmEps":-0.852035,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1779456600000},"marketStatusCode":1,"adr":0,"listingDate":1674709200000,"exchange":"NASDAQ","adjPreClose":2.92,"postHourTrading":{"tag":"盘后","latestPrice":2.92,"preClose":2.92,"latestTime":"19:07 EDT","volume":17,"amount":50,"timestamp":1779404867885,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.3043005604700777,"impliedVol":4.4961,"impliedVolPercentile":0.988},"requestUrl":"/m/hq/s/GNLX/tweets","defaultTab":"tweets","newsList":[{"id":"2633881004","title":"Genelux Corp reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2633881004","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633881004?lang=en_us&edition=fundamental","pubTime":"2026-05-08 11:38","pubTimestamp":1778211503,"startTime":"0","endTime":"0","summary":"Genelux Corp reports results for the quarter ended March 31 - Earnings SummaryGenelux Corp GNLX.OQ reported a quarterly adjusted loss of 20 cents per share for the quarter ended March 31, higher than ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L06N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633177582","title":"Genelux Q1 net loss widens, misses analyst expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2633177582","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633177582?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:58","pubTimestamp":1778187517,"startTime":"0","endTime":"0","summary":"Genelux Q1 net loss widens, misses analyst expectationsOverviewUS immuno-oncology firm's Q1 net loss widened, missing analyst expectationsQ1 loss from operations also missed analyst expectationsOperat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nL1N41K1OM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633778321","title":"Genelux Q1 EPS $(0.20), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2633778321","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633778321?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:55","pubTimestamp":1778187340,"startTime":"0","endTime":"0","summary":"Genelux Q1 EPS $(0.20), Inline","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/GNLX","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Genelux Q1 EPS $(0.20), Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633172180","title":"Genelux Q1 2026 net loss widens to $8.9 million; no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2633172180","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633172180?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:42","pubTimestamp":1778186567,"startTime":"0","endTime":"0","summary":"Genelux posted a net loss of USD 8.93 million for the three months ended March 31, 2026, widening from USD 7.49 million a year earlier.Total operating expenses rose to USD 9.17 million from USD 7.82 million, led by research and development spending of USD 5.78 million versus USD 4.7 million.Cash, cash equivalents, restricted cash, and marketable securities totaled USD 26.3 million as of March 31, 2026; cash runway expected to last into the first quarter of 2027.Business updates included interim lung cancer data for intravenous Olvi-Vec in SCLC  and NSCLC , plus a January underwritten stock offering that raised USD 18.5 million in net proceeds.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original con","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260507:nNDL8CLpLs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633171836","title":"Press Release: Genelux Corporation Reports First Quarter Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2633171836","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633171836?lang=en_us&edition=fundamental","pubTime":"2026-05-08 04:15","pubTimestamp":1778184900,"startTime":"0","endTime":"0","summary":"-- Topline data from randomized Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 --. -- Systemic lung cancer programs advancing with additional updates expected throughout 2026 --. WESTLAKE VILLAGE, Calif., May 07, 2026  -- Genelux Corporation , a late clinical-stage immuno-oncology company, today announced financial results for the first quarter of 2026 and provided general business updates.\"In parallel, we are making steady progress in advancing our manufacturing and operational capabilities to support the continued development of Olvi-Vec and position the Company for potential commercial readiness. Our focus remains on establishing the necessary supply, quality, and organizational infrastructure as our registration-directed programs advance,\" concluded Mr. Zindrick.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4099","BK4588","PFS","TM","GNLX","PLTM","BK4604","BK4139","BK4585","BK4555","BK4211","03160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632625583","title":"Genelux Corp  expected to post a loss of 18 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2632625583","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632625583?lang=en_us&edition=fundamental","pubTime":"2026-05-02 06:53","pubTimestamp":1777675985,"startTime":"0","endTime":"0","summary":"Genelux Corp  expected to post a loss of18cents a share - Earnings Preview Genelux Corp GNLX.OQ GNLX.O is expected to  show no change in quarterly revenue when it reports  results on May 4 (estimated)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260501:nL8N41E265:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631051624","title":"Genelux announces annual shareholder meeting webcast","url":"https://stock-news.laohu8.com/highlight/detail?id=2631051624","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631051624?lang=en_us&edition=fundamental","pubTime":"2026-04-29 20:03","pubTimestamp":1777464227,"startTime":"0","endTime":"0","summary":"Genelux schedules annual shareholder meeting for June 16, 2026 in virtual format.Shareholders will vote on election of one Class I director, with John Smither nominated for a term ending at 2029 annual meeting.Meeting will also seek shareholder ratification of Weinberg & Company, P.A. as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on April 29, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260429:nNDL8xqYMg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621016557","title":"Genelux announces Olvi-Vec partnership payment of USD 11 million from Newsoara Biopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2621016557","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621016557?lang=en_us&edition=fundamental","pubTime":"2026-03-23 21:56","pubTimestamp":1774274184,"startTime":"0","endTime":"0","summary":"Genelux outlined plans to commercialize Olvi-Vec in the US initially for ovarian cancer, positioning it around a platinum resensitization approach intended to expand treatment options in later-line disease.Pipeline development includes an ongoing Phase 3 trial in platinum resistant or refractory ovarian cancer, with topline results expected in 2H 2026.Systemic administration programs in recurrent lung cancers are being advanced to broaden potential use beyond regional delivery and support expansion into additional tumor types.Greater China rights have been partnered with Newsoara Biopharma, which has paid USD 11.0 million to date, with Genelux eligible for additional milestones and royalties.Management cited an estimated annual market opportunity of more than USD 1.0 billion, supported by a strategy that combines self-manufacturing with targeted commercialization in a concentrated prescriber network.Disclaimer: This news brief was created by Public Technologies  using generative artifi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL480HDC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620089730","title":"Genelux Is Maintained at Speculative Buy by Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2620089730","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620089730?lang=en_us&edition=fundamental","pubTime":"2026-03-20 23:55","pubTimestamp":1774022100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GNLX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 20, 2026 11:55 ET (15:55 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620073656","title":"Genelux price target lowered to $20 from $23 at Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2620073656","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620073656?lang=en_us&edition=fundamental","pubTime":"2026-03-20 20:36","pubTimestamp":1774010189,"startTime":"0","endTime":"0","summary":"Benchmark lowered the firm’s price target on Genelux (GNLX) to $20 from $23 and keeps a Speculative Buy rating on the shares after adjusting the fi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/genelux-price-target-lowered-to-20-from-23-at-benchmark-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/genelux-price-target-lowered-to-20-from-23-at-benchmark-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GNLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620780235","title":"Genelux Corp : Benchmark Cuts Target Price to $20 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2620780235","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620780235?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:09","pubTimestamp":1774004978,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nFWN40809Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GNLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620720029","title":"U.S. RESEARCH ROUNDUP-Air Products, Chevron, FedEx","url":"https://stock-news.laohu8.com/highlight/detail?id=2620720029","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620720029?lang=en_us&edition=fundamental","pubTime":"2026-03-20 14:50","pubTimestamp":1773989443,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Air Products, Chevron, FedExMarch 20 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Air Products,","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL4N4080E4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CAG","EL","ATR","BSX","CQP","BRZE","LU2357305700.SGD","ALMS","COHX","FDX","CDNL","LNG","FRPT","COHR","CCK","XOM","DRIO","EOG","APD","XOMZ","CAKE","GNLX","XOMO","AR","EXE","XOMX","FANG","CRC","CMG","DRI","CNX","FLNC","LU0211327993.USD","ALL","FIVE","CRGY","AEIS","ETON","FCFS","CEVA","GAP","APA","LU0154236417.USD","FIGS","CVX","LU2211815571.USD","AMH","TGT","CMGG","COP"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620716972","title":"Genelux Corp reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2620716972","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620716972?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:01","pubTimestamp":1773954102,"startTime":"0","endTime":"0","summary":"Genelux Corp reports results for the quarter ended December 31 - Earnings SummaryGenelux Corp GNLX.OQ reported a quarterly adjusted loss of 25 cents per share for the quarter ended December 31, higher","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nL8N4072WT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620527189","title":"Genelux signs equity distribution deal with TD Cowen for up to USD 100 million offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2620527189","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620527189?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:53","pubTimestamp":1773953612,"startTime":"0","endTime":"0","summary":"Genelux entered a sales agreement with TD Cowen to offer and sell common stock with aggregate gross proceeds of up to USD 100 million.Shares may be sold from time to time through at-the-market transactions, including block trades.TD Cowen will receive compensation of up to 3% of the gross proceeds from any shares sold under the agreement.Net proceeds are intended for general corporate purposes, including research and development and clinical trial expenses.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 19, 2026, an","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL8Cxp2g:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620691279","title":"Genelux Q4 EPS $(0.24) Misses $(0.21) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2620691279","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620691279?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:30","pubTimestamp":1773952256,"startTime":"0","endTime":"0","summary":"Genelux (NASDAQ:GNLX) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.21) by 12.68 percent. This is a 4 percent increase over losses of $(0.25) per share from the same","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51368899/genelux-q4-eps-0-24-misses-0-21-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Genelux Q4 EPS $(0.24) Misses $(0.21) Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","GNLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620276012","title":"Press Release: Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2620276012","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620276012?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:15","pubTimestamp":1773951300,"startTime":"0","endTime":"0","summary":"-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 --. -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in relapsed small cell lung cancer  and early signs of anti-tumor activity in non-small cell lung cancer ; additional updates expected throughout 2026 --. -- Appointed Jason Litten, M.D., as Chief Medical Officer to lead clinical development strategy --. -- $33.1 million in pro forma cash, cash equivalents, marketable securities and restricted cash as of December 31, 2025, including $18.5 million in net proceeds from underwritten offering of common stock in January 2026; expected to support operations into 1Q27--. WESTLAKE VILLAGE, Calif., March 19, 2026  -- Genelux Corporation , a late clinical-stage immuno-oncology company, today announced fourth quarter and full year 2025 financial results and business updates.\"In parallel, we are advancing our manufacturing and operational capabilities to","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4195","BK4139","PLTM","BK4211","PFS","GNLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620127640","title":"Genelux FY 2025 net loss widens 7.62% to USD 32.15 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620127640","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620127640?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:08","pubTimestamp":1773950932,"startTime":"0","endTime":"0","summary":"Genelux published its Annual Report on Form 10-K for the fiscal year ended Dec. 31, 2025.Net loss widened 7.6% to USD 32.15 million, while revenue was USD 8,000.Research and development expense rose 5.5% to USD 19.85 million, driven primarily by higher clinical and regulatory costs tied to the Phase 3 On Prime/GOG-3076 registration trial.General and administrative expense increased 5.2% to USD 13.37 million, mainly reflecting higher employee compensation from annual salary increases and headcount changes, partly offset by lower consulting services.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Ret","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL6MVGZX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617863051","title":"Genelux Corp  expected to post a loss of 22 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2617863051","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617863051?lang=en_us&edition=fundamental","pubTime":"2026-03-07 04:24","pubTimestamp":1772828648,"startTime":"0","endTime":"0","summary":"Genelux Corp  expected to post a loss of22cents a share - Earnings Preview Genelux Corp GNLX.OQ GNLX.O is expected to  show no change in quarterly revenue when it reports  results on March 9 (estimate","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nL8N3ZU2HQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616306478","title":"Genelux Director Thomas John Disposes of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2616306478","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616306478?lang=en_us&edition=fundamental","pubTime":"2026-03-04 09:05","pubTimestamp":1772586338,"startTime":"0","endTime":"0","summary":"Thomas John, a director of Genelux Corporation, reported a disposal of 10,000 shares of the company’s common stock. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genelux Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260304:nNDLPdZfg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Genelux Director Thomas John Disposes of Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GNLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614851263","title":"MBX Biosciences Says CFO to Step Down; Names Interim Finance Chief","url":"https://stock-news.laohu8.com/highlight/detail?id=2614851263","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614851263?lang=en_us&edition=fundamental","pubTime":"2026-02-27 22:08","pubTimestamp":1772201314,"startTime":"0","endTime":"0","summary":"MBX Biosciences  said Friday that Chief Financial Officer Richard Bartram will step down, effective March 15, and that John Smither has been named interim CFO.The company said in a regulatory filing that Bartram will serve as a consultant to the company following his resignation and that it has begun a search for a new CFO.MBX said Bartram's departure is not related to any disagreement with the company or its auditors.Smither is a former CFO of Arcutis Biotherapeutics  and is currently a member of the boards of NewAmsterdam Pharma  and Genelux Corporation .Shares of MBX Biosciences were 1.3% lower in recent premarket trading.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GNLX","MBX","ARQT","BK4139","NAMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.genelux.com","stockEarnings":[{"period":"1week","weight":-0.0395},{"period":"1month","weight":0.1406},{"period":"3month","weight":0.1061},{"period":"6month","weight":-0.4113},{"period":"1year","weight":0.1727},{"period":"ytd","weight":-0.3303}],"compareEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":0.0549},{"period":"3month","weight":0.0773},{"period":"6month","weight":0.127},{"period":"1year","weight":0.2743},{"period":"ytd","weight":0.0892}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":0.012999},{"month":2,"riseRate":0.75,"avgChangeRate":0.366223},{"month":3,"riseRate":0.25,"avgChangeRate":0.051084},{"month":4,"riseRate":0.25,"avgChangeRate":-0.136176},{"month":5,"riseRate":0.5,"avgChangeRate":-0.002731},{"month":6,"riseRate":0.666667,"avgChangeRate":0.036149},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.058289},{"month":8,"riseRate":0.666667,"avgChangeRate":0.080908},{"month":9,"riseRate":1,"avgChangeRate":0.122082},{"month":10,"riseRate":0.666667,"avgChangeRate":0.291649},{"month":11,"riseRate":0,"avgChangeRate":-0.218784},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.053731}],"exchange":"NASDAQ","name":"Genelux Corporation","nameEN":"Genelux Corporation"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Genelux Corporation(GNLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Genelux Corporation(GNLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Genelux Corporation,GNLX,Genelux Corporation股票,Genelux Corporation股票老虎,Genelux Corporation股票老虎国际,Genelux Corporation行情,Genelux Corporation股票行情,Genelux Corporation股价,Genelux Corporation股市,Genelux Corporation股票价格,Genelux Corporation股票交易,Genelux Corporation股票购买,Genelux Corporation股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Genelux Corporation(GNLX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Genelux Corporation(GNLX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction